2,914 material Form 8-K filings that 2,352 companies we cover made with the SEC in August 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Abacus furnished a shareholder letter dated August 24, 2026, from Chief Investment Officer Elena Plesco, covering interest rates, a valuation methodology change, and first-half 2026 results. The letter says Q2 2026 revenue grew 30% year over year to $73.0 million and adjusted net income reached $27.1 million, above the high end of company guidance. The company also moved to a Historical Return Method for valuing policies starting in Q2 2026, which shareholders may want to weigh alongside the reported results.
Q2 2026 revenue grew 30% year over year to $73.0 million, led by Life Solutions, which grew 38.3%.
Adjusted net income was $27.1 million, above the high end of company guidance; adjusted EBITDA grew 27% to $39.9 million.
Starting in Q2 2026, policies are valued under an updated Historical Return Method that applies observed returns to cost basis instead of discounting modeled cash flows.
Capital deployed was close to $200 million in Q2 2026 and $362 million year to date; adjusted figures are non-GAAP measures.
Erasca announced that the FDA granted Fast Track Designation to ERAS-0015 for metastatic pancreatic adenocarcinoma. The designation can allow more frequent FDA interactions and may expedite review, but it does not change approval standards or increase the likelihood of U.S. marketing approval.
FDA granted Fast Track Designation to ERAS-0015 for metastatic pancreatic adenocarcinoma, announced August 24, 2026.
Designated programs may gain more frequent FDA interactions and may be eligible for accelerated approval, priority review, or rolling review if criteria are met.
The FDA may later revoke the designation or decide review timing will not be shortened.
The company plans a phase 3 trial in pancreatic cancer and two potentially registration-enabling lung cancer trials.
Kimbell Royalty Partners completed the $221.2 million Drop Down acquisition of mineral and royalty interests from affiliated sellers on August 21, 2026, paying about $75 million in cash and issuing 9,500,000 OpCo Common Units and an equal number of Class B Units. On August 24, 2026, it raised its guidance, with midpoint Q3 and Q4 2026 production now 10% and 15% above the midpoint of prior 2026 guidance. The new units are exchangeable into Common Units and will be covered by a resale registration statement that Kimbell must file within 5 business days of the closing.
Drop Down closed August 21, 2026: about $75 million in cash plus 9,500,000 OpCo Common Units and Class B Units (OpCo units valued at about $146.3 million)
Q3 2026 net production guidance of 26.5 to 29.5 Mboe/d; Q4 2026 guidance of 27.7 to 30.7 Mboe/d
Midpoint of guidance is 10% higher for Q3 and 15% higher for Q4 than prior 2026 guidance; cash G&A per Boe guidance lowered
Shelf registration statement to be filed within 5 business days of closing and made effective within 120 days
Comstock Inc. closed the sale of its mineral, mining, processing and mining-district real estate entities to Mackay Precious Metals Inc., a subsidiary of Mackay Gold & Silver Corp. The company says the transaction, valued at more than $45 million, reduces ongoing costs and enhances balance sheet liquidity, and it expects a gain of about $10 million to $12 million.
Comstock has received $20 million in cash and 2 million Mackay Gold & Silver common shares, currently valued at about $4.5 million
Expected gain of about $10 million to $12 million, with no cash taxes expected on the gain
A secured second-tranche payment of $7 million is due within 18 months
Estimated annual operational savings of $1.5 million; Comstock retains a 1.5% NSR royalty and a $10 million contingent payment tied to a mine construction decision or a change-of-control deal of at least $500 million within seven years
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.